Clinical Trials on Carcinoma Non-small Cell Lung

Total 18581 results

University Health Network, Toronto

Active, not recruiting

Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC)

Non-small Cell Lung Carcinoma

Canada
European Lung Cancer Working Party

Active, not recruiting

Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.

Non Small Cell Lung Carcinoma

Belgium
European Lung Cancer Working Party

Terminated

Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer

Non-small Cell Lung Carcinoma

Belgium, France, Spain, Greece
University Hospital, Strasbourg, France

Completed

Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients

Small Cell Lung Cancer | Non-Small Cell Lung Carcinoma

France
University of Washington
National Cancer Institute (NCI)

Recruiting

PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Bristol-Myers Squibb

Completed

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate057)

Non-Squamous Cell Non-small Cell Lung Cancer

United States, Germany, Hong Kong, Spain, Australia, Mexico, Austria, France, Singapore, Switzerland, Canada, Poland, Argentina, Brazil, Chile, Czechia, Hungary, Italy, Norway, Peru, Romania, Russian Federation
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer

Advanced Non-squamous Cell Non-small Cell Lung Cancer

China
Hellenic Cooperative Oncology Group
Stavros Niarchos Foundation; Care Across Ltd

Recruiting

Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer (SNF-CLIMEDIN)

Non-Small Cell Carcinoma of Lung, TNM Stage 4

Greece
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer

Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7

United States, Canada
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
Jonsson Comprehensive Cancer Center
Eli Lilly and Company; Genentech, Inc.

Active, not recruiting

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8

United States
Tongji University

Recruiting

Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma (ATHEM)

NSCLC | EGF-R Positive Non-Small Cell Lung Cancer

China
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

Lung Cancer | Advanced or Metastatic Non-Small-Cell Lung Cancer | Resectable Non-Small-Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Hong Kong, Israel, United Kingdom
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer

ROS1 Rearrangement Non-small Cell Lung Cancer | ALK Rearrangement Non-small Cell Lung Cancer

China
Shanghai Chest Hospital

Recruiting

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Non-small Cell Lung Cancer Metastatic | EGF-R Positive Non-Small Cell Lung Cancer

China
Washington University School of Medicine
Eli Lilly and Company

Completed

Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer

United States
Royal Marsden NHS Foundation Trust
Bristol-Myers Squibb

Active, not recruiting

SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects (STILE)

Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage II

United Kingdom
Alliance Foundation Trials, LLC.
AstraZeneca

Active, not recruiting

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Regione Lombardia

Completed

Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial (ONC-MANILA12)

Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV

Italy
Maastricht Radiation Oncology
University Medical Center Groningen; The Netherlands Cancer Institute

Completed

Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC (NVALT11)

Non Small Cell Lung Cancer (NSCLC) | Stage III Non-Small Cell Lung Cancer | Radical Treatment

Netherlands
QLT Inc.

Terminated

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

Stage IV Non-small Cell Lung Cancer | Stage IIIb Non-small Cell Lung Cancer
QLT Inc.

Terminated

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

Stage IV Non-small Cell Lung Cancer | Stage IIIb Non-small Cell Lung Cancer
Schwartzberg, Lee, M.D.
Amgen

Completed

Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma

Non-small Cell Lung Cancer

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7 | EGFR Exon 19 Deletion Mutation | EGFR NP_005219.2:p.L858R

United States
EMD Serono

Completed

Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer

Lung Cancer | Non Small Cell Lung Carcinoma

United States, Germany, Austria
Holy Cross Hospital, Florida

Terminated

Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer (HCH003)

Non-Small-Cell Lung Carcinoma

United States
Shanghai Chest Hospital

Unknown

Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)

Carcinoma | Non-small Cell Lung Cancer
City of Hope Medical Center
National Cancer Institute (NCI); CytoImmune Therapeutics

Active, not recruiting

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer... and other conditions

United States
Juravinski Cancer Center

Unknown

Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body RadioTherapy and REsection (LINNEARRE-I)

Carcinoma | Non-Small-Cell Lung Cancer

Canada
National University Hospital, Singapore

Recruiting

Osimertinib for Advanced EGFR-positive NSCLC Patients

Non Small Cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer

Singapore
Greg Durm, MD
AstraZeneca; Indiana University School of Medicine

Terminated

Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Stage III Non-small-cell Lung Cancer

United States
National Cancer Institute, Naples

Active, not recruiting

MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer (MILES-3)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB

Italy
Zhejiang Provincial People's Hospital

Withdrawn

Abscopal Effect for Metastatic Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer | Radiotherapy | Metastatic Non-small Cell Lung Cancer | Thymalfasin
First People's Hospital of Hangzhou

Completed

T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure

Non-small Cell Lung Cancer Stage III | Non-Small-Cell Lung Cancer Metastatic

China
First People's Hospital of Hangzhou

Completed

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

Non-small Cell Lung Cancer Stage III | Non-Small-Cell Lung Cancer Metastatic

China
Gradalis, Inc.

Withdrawn

Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer

Lung Neoplasms | Advanced Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7 | Mesothelin Positive

United States
Washington University School of Medicine
Varian Medical Systems

Recruiting

Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Early Stage Non-small Cell Lung Cancer

United States
Mirati Therapeutics Inc.

Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer

United States, Korea, Republic of, Italy, Spain, Czechia, Hungary, Netherlands, Canada, Australia, Austria, Belgium, Germany, Ireland, Israel, Poland, United Kingdom, Taiwan, Portugal
Worldwide Innovative Network Association
Pfizer; ARC Foundation for Cancer Research

Terminated

Survival Prolongation by Rationale Innovative Genomics (SPRING)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB

Israel, United States, Luxembourg, Spain
Indiana University

Completed

Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer

Healthy | Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic

United States
Ohio State University Comprehensive Cancer Center
National Institute on Aging (NIA)

Completed

Resiliency Among Older Adults Receiving Lung Cancer Treatment (ROAR-LCT)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Advanced Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Unresectable Lung Carcinoma

United States
Jonathan Riess
National Cancer Institute (NCI)

Not yet recruiting

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Ethicon, Inc.

Terminated

NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung

Non-Small Cell Lung Cancer | Lung Cancer | Neoplasms, Lung | Carcinoma, Non-Small Cell Lung | Non-Small-Cell Lung Carcinoma | Cancer of Lung | Cancer of the Lung

United States
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Non-squamous Non-small-cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.

Non-squamous Non-small Cell Lung Cancer

China
Yongchang Zhang

Recruiting

Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study (SAVE)

Non-Squamous Non Small Cell Lung Cancer

China
Sanofi

Active, not recruiting

Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (CARMEN-LC06)

Non-squamous Non-small Cell Lung Cancer

Belgium, Italy, Spain, Japan, United States, France, Turkey
Boehringer Ingelheim

Completed

The START Study Observes Afatinib as First-line Treatment and Sequential Therapy in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Nonsmall Cell Lung Cancer

Non-squamous, Non-Small Cell Lung Cancer

China
Boehringer Ingelheim

Completed

The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib (UpSwinG)

Non-squamous, Non-Small Cell Lung Cancer

United Kingdom

Clinical Trials on Carcinoma Non-small Cell Lung

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations